Regulatory Approval
Alembic Pharmaceuticals Receives USFDA Final Approval for Tretinoin Cream USP 0.05%
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals Limited has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tretinoin Cream USP, 0.05%, a generic equivalent of Bausch Health’s Retin-A Cream. The approval strengthens Alembic’s dermatology portfolio in the U.S. market and expands its regulated market product pipeline.
PRICE-SENSITIVE TRIGGER
Event: USFDA Final Approval for Tretinoin Cream USP, 0.05%
Type: Regulatory Approval / Product Approval
Impact: Positive
Immediate Effect: Alembic is now authorized to market Tretinoin Cream USP, 0.05% in the United States, enabling entry into a product market with an estimated annual size of US$76 million.
Key Metrics:
- Estimated U.S. Market Size: US$76 million (12 months ended March 2026, IQVIA)
- Total USFDA ANDA Approvals: 242
- Final Approvals: 222
- Tentative Approvals: 20
Highlight:
- Tretinoin Cream USP, 0.05% addresses a U.S. market estimated at US$76 million annually and increases Alembic’s cumulative USFDA ANDA approvals to 242.
What Happened ?
Alembic Pharmaceuticals announced that it has received final approval from the USFDA for its ANDA for Tretinoin Cream USP, 0.05%.
The approved product is therapeutically equivalent to Retin-A Cream, 0.05%, marketed by Bausch Health US, LLC. Tretinoin Cream is indicated for topical treatment of acne vulgaris.
The approval allows Alembic to commercialize the product in the U.S. generic pharmaceuticals market and further strengthens its dermatology portfolio within regulated international markets.
Key Details
USFDA Final Approval – Tretinoin Cream USP 0.05%:
- Received final USFDA approval for ANDA Tretinoin Cream USP, 0.05%.
- Product is therapeutically equivalent to Retin-A Cream, 0.05%.
- Reference Listed Drug (RLD) owned by Bausch Health US, LLC.
- Product indicated for treatment of acne vulgaris.
- U.S. market opportunity estimated at US$76 million.
- Approval adds another commercial product opportunity in the regulated U.S. market.
- Total cumulative ANDA approvals now stand at 242.
- Alembic currently holds 222 final approvals and 20 tentative approvals from USFDA.
Note:
- The approval pertains to a generic dermatology product and supports Alembic’s ongoing strategy of expanding its U.S. generics portfolio through regulated market filings and approvals.
Risk Analysis
Summary:
- While regulatory approval removes approval-related uncertainty, commercial success will depend on market competition, pricing dynamics, customer acquisition, and product launch execution in the U.S. generic market.
Key Risks:
- Generic pharmaceutical markets typically face pricing pressure.
- Revenue realization depends on commercialization timelines and market share capture.
- Competition from existing and future generic entrants may impact profitability.
- Market opportunity estimates do not guarantee actual sales performance.
- Product contribution to earnings will depend on manufacturing scale and distribution execution.
Worst Case Scenario:
- The product may face intense generic competition leading to lower-than-expected market penetration, pricing pressure, and limited financial contribution despite receiving regulatory approval.
Risk Level: Low
Company Commentary
- Alembic has received final USFDA approval for Tretinoin Cream USP, 0.05%.
- The approved product is therapeutically equivalent to Retin-A Cream.
- Tretinoin Cream is indicated for the treatment of acne vulgaris.
- The company now has a cumulative total of 242 ANDA approvals from the USFDA.
- Alembic continues to strengthen its presence in regulated international pharmaceutical markets.
Official Exchange Filing: Alembic Pharmaceuticals Limited
